Drug and Therapeutics Bulletin 2001;39:25-27; doi:10.1136/dtb.2001.39425
Copyright © 2001 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

Failings in treatment advice, SPCs and black triangles

When Drug and Therapeutics Bulletin reviews a new medicine, one of our sources of information is the summary of product characteristics (SPC).1 This legal document provides advice about the product, including its unwanted effects and how these might be avoided. When referring to a new medicine, we include a &#9660 in the text (see page 30, this issue). The Committee on Safety of Medicines/Medicines Control Agency (CSM/MCA) asks that this symbol be used to indicate when healthcare professionals should use a 'Yellow Card' to report any suspected adverse reaction. Here, we present evidence of weaknesses in the safety aspects of the SPC system and accompanying flaws in the Black Triangle Scheme.






About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 2001 BMJ Publishing Group Ltd.